Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial

European Urology Oncology · Elsevier

Аннотация

Publication date: Available online 5 October 2026 Source: European Urology Oncology Author(s): Niven Mehra, Noel W. Clarke, Andrew J. Armstrong, Mototsugu Oya, Neal Shore, Giuseppe Procopio, João Daniel Guedes, Cagatay Arslan, Emma Brown, Jae Young Joung, Mikio Sugimoto, Young Deuk Choi, Daniel Castellano, Yüksel Ürün, Christian Hosius, David McGuinness, Arnold Degboe, Fred Saad

Читать у издателя →

Похожие статьи